Latest news with #Exagen
BBC News
07-08-2025
- Business
- BBC News
Northumberland solar farm rejected over harm to 'rural paradise'
A large-scale solar farm planned for a swathe of countryside has been refused, over concerns it would be a "wanton destruction of a rural paradise."Renewable energy firm Exagen had put forward plans to build Highfield Energy Park on the site, near the village of Whittonstall, in Northumberland, but it was voted down by Northumberland County Council planning firm had proposed erecting more than 90,000 solar panels across 271 acres (110 hectares), which they said would power 21,300 homes and save 27,900 tonnes of carbon dioxide (CO2) emissions per plans had previously been earmarked for approval, despite more than 140 public objections, but were overturned at a hearing. Resident Adam Brown said the impact of the proposed solar farm, located between two wind farms, would be "overwhelming", adding there would not be sufficient access to the site for emergency services in the case of a was joined by other objectors, including Kevin Rooney, who said there had been a "catastrophic" error in the site's drainage designs that risked causing flooding in the neighbouring which recently won approval for a major solar park across 30 fields between Greenside, Coalburns, and Chopwell, just over the border in rural Gateshead, said the solar farm was needed to meet the government's targets to significantly boost solar energy production by 2030. 'Missed opportunity' Exagen's Andrew Mott the impact of the scheme on the green belt had been "kept to a minimum", and that the site was the "only viable location" in the area to connect to the electricity Northumberland county councillor Colin Horncastle, said: "I think we all agree with renewable energy, but we cannot have renewable energy at any price. "This is purely wanton destruction of a rural paradise." The plans were spread across two sites totalling 271 acres, one of which would have hosted the solar farm and another for a substation - with the sites connected via an underground Mott suggested the substation site, north of Lynn Burn, should be deemed 'grey belt' – a new term introduced under the Labour government to identify lower quality green belt land where building can be the public benefits of the solar farm would be sufficient to justify its development regardless, he committee chair, Trevor Thorne, was among the supporters of the project. He said Northumberland was "missing a big opportunity" by denying the application, especially given the land was previously used for opencast mining rather than being an area of countryside that had hitherto been East independent councillor Georgina Hill moved for the refusal of the plans, however, saying: "It [the landscape] is just stunning and it would be so wrong to approve this." The committee voted by an 11 to four margin to reject the scheme, sparking applause from members of the public who had attended the Morpeth hearing to oppose the application. Follow BBC North East on X, Facebook, Nextdoor and Instagram.
Yahoo
24-07-2025
- Business
- Yahoo
Exagen Inc. (XGN): A Bull Case Theory
This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 Promising SmallCap Stocks Under $1 Billion Market Cap. We came across a bullish thesis on Exagen Inc. on by inflection99. In this article, we will summarize the bulls' thesis on XGN. Exagen Inc.'s share was trading at $7.00 as of July 16th. A doctor reading the results of a Phase 2 clinical trial of treatments for cancer, infectious diseases and autoimmune and inflammatory diseases. Exagen (XGN) is a molecular diagnostics company specializing in autoimmune diseases like lupus and rheumatoid arthritis, primarily serving rheumatologists with its proprietary AVISE® test suite. Its flagship product, AVISE CTD, offers superior diagnostic capabilities versus the standard of care, combining multiple tests with enhanced sensitivity and specificity, reducing diagnosis time, hospitalizations, and repeat testing. The autoimmune diagnostics market is large, underserved, and economically attractive to all stakeholders—patients, providers, and payers—due to better outcomes, cost savings, and improved practice efficiency. This favorable market backdrop is amplified by the emergence of novel lupus therapies, increasing pharma's incentive to partner with diagnostics players like Exagen. The company holds key advantages through its proprietary biomarkers, unique reimbursement code, and growing coverage with Medicare and commercial payers. Recent innovations, such as new T-cell markers and early kidney disease detection, support pricing power, gross margin expansion, and potential biopharma revenue. Led by CEO John Aballi—who previously executed a similar playbook at Decipher before selling to Veracyte—Exagen has transformed from a cash-burning operation to near breakeven, with revenue acceleration, ASP tailwinds, and profitability expected by Q4 2025. Strategic interest is also plausible; Labcorp recently highlighted autoimmune disease as a priority area, positioning Exagen as a potential acquisition target. With minimal sell-side coverage, recent capital raises, and multiple upcoming catalysts—including improved reimbursement, guideline inclusion, and biopharma partnerships—Exagen is poised for a re-rating. Applying a conservative 4.5x 2026E revenue multiple implies 2.5–3x upside from current levels, while downside appears limited given the business's turnaround, strategic value, and current low-end peer valuation. Previously, we covered a bullish thesis on Oscar Health, Inc. (OSCR) by Oguz Erkan in May 2025, which highlighted the company's tech-driven platform, margin improvement, and expansion opportunity in ACA markets. The company's stock price has appreciated by approximately 21.62% since our coverage. This is because the thesis played out. Inflection99 shares a similar view on Exagen but emphasizes its autoimmune diagnostics advantage. Exagen Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 8 hedge fund portfolios held XGN at the end of the first quarter which was 7 in the previous quarter. While we acknowledge the potential of XGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-06-2025
- Business
- Yahoo
Exagen Insider Ups Holding During Year
From what we can see, insiders were net buyers in Exagen Inc.'s (NASDAQ:XGN ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it. Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. The CFO & Corporate Secretary Jeffrey Black made the biggest insider purchase in the last 12 months. That single transaction was for US$66k worth of shares at a price of US$2.98 each. We do like to see buying, but this purchase was made at well below the current price of US$7.00. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below! View our latest analysis for Exagen Exagen is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket. For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. It appears that Exagen insiders own 8.8% of the company, worth about US$13m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders. The fact that there have been no Exagen insider transactions recently certainly doesn't bother us. But insiders have shown more of an appetite for the stock, over the last year. Insiders own shares in Exagen and we see no evidence to suggest they are worried about the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For example - Exagen has 3 warning signs we think you should be aware of. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. — Investing narratives with Fair Values A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029. By Agricola – Community Contributor Fair Value Estimated: CA$12.29 · 0.9% Overvalued DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts By WynnLevi – Community Contributor Fair Value Estimated: $195.39 · 0.9% Overvalued Historically Cheap, but the Margin of Safety Is Still Thin By Mandelman – Community Contributor Fair Value Estimated: SEK232.58 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
08-05-2025
- Business
- Yahoo
Exagen Inc. Prices Public Offering of Common Stock
CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share. All of the shares in the offering will be sold by Exagen, with gross proceeds to Exagen expected to be $17,587,500 before deducting underwriting discounts and commissions and offering expenses. Exagen has granted the underwriters a 30-day option to purchase up to an additional 502,500 shares on the same terms and conditions. The offering is expected to close on May 9, 2025, subject to the satisfaction of customary closing conditions. Canaccord Genuity is acting as sole bookrunner for the offering. The public offering is being made pursuant to a shelf registration statement on Form S-3 (including a base prospectus) that was previously filed with the Securities and Exchange Commission (the 'SEC') on November 17, 2023, as amended on November 27, 2023, and declared effective by the SEC on November 29, 2023. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's website located at Copies of the final prospectus supplement and the accompanying prospectus relating to this offering, when available, can be obtained from Canaccord Genuity LLC, Attention: Syndication Department, 1 Post Office Square, Suite 3000, Boston, MA 02109, or by email at prospectus@ This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Exagen Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen's mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The Company's flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren's syndrome earlier and with greater accuracy. Exagen's laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE®-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management. For more information, please visit or follow @ExagenInc on X. Forward-Looking Statements Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the completion of the public offering and other risks and uncertainties that are described under the heading 'Risk Factors' in Exagen's preliminary prospectus filed with the SEC on May 7, 2025, Exagen's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 11, 2025 and any subsequent filings with the SEC. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact:Ryan DouglasExagen in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-04-2025
- Business
- Yahoo
Garden ‘paradise' under threat from 100-acre solar farm
A garden 'paradise' is under threat from a 100-acre solar farm. Tom Stuart-Smith, the award-winning garden designer, said his family's garden would be at risk if St Albans city and district council approved plans for the Beechtree Junction solar farm less than one mile away. The garden, which has been in his family for four generations, is in Serge Hill, Hertfordshire, and under the plans would be surrounded by 11 fields of solar panels. The company behind the scheme says it will generate enough electricity to power 13,000 homes for 40 years, adding that an electricity substation would also be built about a quarter of a mile from Serge Hill. But Mr Stuart-Smith, 65, described the 'huge' solar farm as a 'short-sighted tragedy'. He said: 'There is one view I have always cherished from somewhere with the delightful name of Ragged Hall Lane. Under the proposal, this view would now be over acres of solar panels.' Exagen, the applicants for the solar farm, has outlined plans on its website to create a wildflower meadow and allow local beekeeping groups to use hives on the site. Bird and bat boxes will also be installed and new hedgerows planted, the company says. Mr Stuart-Smith, who has designed eight gold medal-winning gardens at the Chelsea Flower Show, has lived at Serge Hill since 1990 with his wife, Sue, a psychotherapist. From there, they run a not-for-profit community garden that aims to improve people's mental health and creativity. 'Next year marks 100 years since my grandfather Tom Motion bought Serge Hill. It's hard to imagine what it might be like in another 100 years,' Mr Stuart-Smith told the Times. 'Within a mile we have one planning proposal to remove 40 acres of woodland for a golf course and another to cover about 100 acres with solar panels. 'We all need clean power. Not so sure about golf, but this seems a short-sighted tragedy. The future of open land on the urban fringe has to be as a resource for all. 'I'm not against the proposal in principle, but the current layout shown is completely indiscriminate and inconsiderate.' The land, currently used by walkers and families, is a habitat for white admiral butterflies which Mr Stuart-Smith described as a 'green lung for the people.' 'Many people walk these lanes, they represent a green lung for the people around here and there are remarkable views over open landscape with fields and woods,' he said. The fields put aside are classified as Grade 3 agricultural land, which means they are be less likely to be useful for farmers. But for Mr Stuart-Smith, the plans risk ruining the land. He said the approach needed was the one used to protect one of the favourite pastimes of past Monarchs, when the area around London was preserved as green space for hunting. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
